July 9, 2026 - Non-regulatory Resomelagon shows reduced inflammation and joint damage in osteoarthritis model
June 29, 2026 - Non-regulatory BIO International USA confirms growing interest in resomelagon and SynAct Pharma following the positive effects of the ADVANCE study
June 15, 2026 - Non-regulatory SynAct Pharma Board of Directors and Management Enter Lock-up Agreements
June 12, 2026 - Non-regulatory SynAct obtains key US patent for resomelagon securing exclusivity until 2044
May 6, 2026 - Non-regulatory SynAct Pharma completes dosing for last patient in Phase 2b ADVANCE study
May 5, 2026 - Non-regulatory SynAct Pharma to participate at the LSX Nordic Congress on May 19-20, 2026 in Copenhagen
March 26, 2026 - Non-regulatory SynAct Pharma doses first patients in the Phase 2 RESOVIR-2 study with resomelagon
March 18, 2026 - Non-regulatory SynAct Pharma Presenting at Partnering and Investor Conference BIO-Europe Spring® 2026 on March 23-25
March 4, 2026 - Non-regulatory Invitation to SynAct Pharma’s Capital Markets Day in Stockholm March 11
February 6, 2026 - Non-regulatory SynAct Pharma successfully reached recruitment goal in Ph2b ADVANCE study
